Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:O76050 (
neu
)
3,969
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interferon (IFN) regulatory factor-1 (
IRF-1
) is a transcription factor that has been historically associated with type I IFN activation and antioncogenic properties. We studied
IRF-1
expression and DNA-binding capacity in nontransformed and transformed mouse fibroblasts. A 43-kDa nuclear
IRF-1
protein was expressed biphasically during the cell cycle in primary mouse embryo fibroblasts, nontransformed NIH 3T3 cells, and ras revertants.
IRF-1
expression became constitutive in ras-transformed NIH 3T3 cells and in cells transformed by oncogenes ets, fes, fos, her-2/
neu
, met, mos, raf, or trk, suggesting that deregulated
IRF-1
expression may be associated with loss of growth control. Lysyl oxidase (LO), a ras suppressor that is downregulated in ras transformants, is an
IRF-1
target gene, but it is not stimulated by abundant
IRF-1
present in transformants, while another
IRF-1
target gene (iNOS) is transcribed.
IRF-1
from either normal or ras-transformed cells bound to IRF elements in the IFN-beta and LO promoters.
IRF-1
in transformants can, therefore, bind to but not transactivate the LO promoter, and the presence of
IRF-1
is not sufficient to suppress ras transformation. LO expression may effect the regulated expression of
IRF-1
: a ras revertant, which was generated by stable transfection of LO cDNA, regained the normal biphasic
IRF-1
pattern. A mainly cytoplasmic, constitutively expressed 46-kDa protein with immunologic identity to the 43-kDa nuclear
IRF-1
was also present in normal and transformed cells, but as it did not bind to the IRF elements, its function is unclear.
...
PMID:Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts. 1465 78
Ex vivo analysis of signaling pathways operating in tumor tissue is complicated by the three-dimensional structure, in particular by stroma-epithelial interactions. Studies performed with pure populations of tumor cells usually do not take into account this issue. One possibility to preserve the tissue architecture is the use of tumor slices. However, diffusion of oxygen and nutrients may become limiting factors, resulting in decreased cell viability and change of tissue morphology, especially after long-term incubation of slices. By using precision cut slices of defined thickness, we were able to establish culture conditions for tumor material obtained from MMTV-
neu
transgenic mice, which allow the study of the action of cytokines and cytotoxic drugs for up to 24 h. A slice thickness of 160 mum was found to be optimal for viability and handling of material. These slices were highly responsive to the action of the cytokine IFN-gamma, as evident form the increase of pY701 STAT1, detected by both immunohistochemistry and western blotting, and by the increase of mRNA levels of the IFN-gamma response genes
IRF-1
, SOCS-1, and STAT1, analyzed by reverse transcriptase-polymerase chain reaction. Furthermore, induction of apoptosis and increase of DNA damage could be monitored after treatment with IFN-gamma or doxorubicin. The slices were also a convenient source for the establishment of explant cultures of tumor epithelial cells. It is concluded that cultivation of precision-cut tumor slices provides a convenient way for the ex vivo molecular analysis of MMTV-
neu
tumor tissue under conditions which closely simulate the situation in vivo and can provide an alternative to in vivo experiments.
...
PMID:Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs. 1953 58